新泰醫藥 MDGL 深 滬
等待開盤 01-12 09:30:00 美东时间
514.06
-42.160
-7.58%
華盛通- 最 高555.10
- 今 開554.99
- 成交量 70.33万股
- 最 低 511.03
- 昨 收 556.22
- 總市值 116.75亿
- 52周最高 615.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 265.00
- 委 比 90.71%
- 總股本 2271.14万
- 歷史最高 615.00
- 量 比 1.74
- 振 幅 7.92%
- 歷史最低 5.25
- 每 手 1
- 風險率 97.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Madrigal Pharmaceuticals Strikes License Agreement With Pfizer For Ervogastat Inhibitor
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license
01-09 21:02
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage DGAT-2 inhibitor, to strengthen its MASH therapy pipeline. DGAT-2 inhibitors reduce liver fat and inflammation, complementing Rezdiffra, Madrigal's liver-targeted therapy. The partnership aims to explore the additive benefits of combining Rezdiffra and ervogastat for MASH treatment. Madrigal plans to present more details at...
01-09 13:00
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, pow...
01-03 02:29
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $900
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price target from $540 to $900.
2025-12-19 20:48
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
On December 15, 2025, Madrigal Pharmaceuticals, Inc. granted 1,394 time-based restricted stock units to 4 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock units vest in four equal installments over four years, contingent on continued employment.
2025-12-18 21:05
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股盘后 | Lululemon Athletica涨10.71%，阿利根尼涨3.86%
Lululemon Athletica涨10.71%；阿利根尼涨3.86%；Roivant Sciences Ltd Ordinary Shares涨2.61%
2025-12-12 07:12
B. Riley Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $670
B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $560 to $670.
2025-12-12 01:01
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to 24 new non-executive employees on December 1, 2025, under its 2025 Inducement Plan. The awards include options for 4,099 shares and 14,630 restricted stock units, with an exercise price of $579.45 per share. Options vest 25% after one year and 6.25% each quarter thereafter, while restricted stock units vest in four equal yearly installments. The company focuses on developing therapeutics for metab...
2025-12-04 21:05
